Table 3 Cancer diagnosis/type, chemotherapy agent class and radiation therapy (Medical Record Review cohort only)
From: Cardiotoxicity after cancer treatment: a process map of the patient treatment journey
N = 46 | Mean (range) | n (%) |
|---|---|---|
Cancer diagnosis | ||
 Age at first cancer diagnosis (years) | 53.6 (6.3–89.3) | 46 (100) |
  Bile duct |  | 1 (2) |
  Breast |  | 14 (30) |
  Colon |  | 1 (2) |
  Hodgkin’s lymphoma |  | 1 (2) |
  Leukaemia |  | 3 (7) |
  Lung |  | 1 (2) |
  Lymphoma |  | 7 (15) |
  Non-Hodgkin’s |  | 11 (24) |
  Oesophagus |  | 1 (2) |
  Osteosarcoma |  | 4 (9) |
  Prostate |  | 1 (2) |
  Missing |  | 1 (2) |
Agent Class | ||
 Chemotherapy cyclesb,c | 5.2 (1–18) |  |
 Alkylating | Mean dose (mg) |  |
  Carboplatin | 520.0 | 2 (4) |
  Chlorambucila |  | 1 (2) |
  Cisplatin | 113.3 | 5 (11) |
  Cyclophosphamide | 1148.1 | 21 (48) |
 Anthracyclines | ||
  Doxorubicin | 462.1 | 18 (39) |
  Epirubicin | 164.0 | 2 (4) |
 Anthracycline combination | ||
  ABVDa |  | 1 (2) |
 Antibiotic cytotoxics | ||
  Bleomycin | 20.0 | 1 (2) |
 Antimetabolites | ||
  ATRA Azacitidine therapy | 100.0 | 1 (2) |
  Adjuvant CTx with carboplatin/gemcitabinea |  | 1 (2) |
  Fluorouracil | 980.0 | 3 (7) |
  Methotrexate | 63.0 | 5 (11) |
  Fludarabine phosphatea |  | 1 (2) |
Mitotic Inhibitors | ||
 Amsacrine | 140.0 | 1 (2) |
 Docetaxel | 145.7 | 4 (9) |
 Etoposide | 200.0 | 1 (2) |
 Paclitaxel | 429.0 | 3 (7) |
 Vincristinea |  | 12 (26) |
Monoclonal Antibodies | ||
 Rituximab | 655.0 | 11 (24) |
 Trastuzumab | 378.1 | 7 (15) |
 Radiation therapy |  | 28 (61) |